Atara Biotherapeutics Inc Quick Ratio (ATRA) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Atara Biotherapeutics Inc   (NASDAQ: ATRA)

Atara Biotherapeutics Inc 's Quick Ratio

ATRA's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 1.45 below Atara Biotherapeutics Inc average.

Within Biotechnology & Pharmaceuticals industry 105 other companies have achieved higher Quick Ratio than Atara Biotherapeutics Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 1684, from total ranking in the first quarter 2026 at 3106.

Explain Quick Ratio?
How much Cash & cash equivalents ATRA´s has?
What are ATRA´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ATRA Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change -52.98 % -88.82 % -88.91 % -88.42 % -90.18 %
Y / Y Cash & cash equivalent Change -55.65 % -39.6 % -80.04 % -79.59 % -36.75 %
Quick Ratio MRQ 1.45 1.48 0.57 0.76 1.53
ATRA's Total Ranking # 1684 # 3106 # 2587 # 1860 # 3803
Seq. Current Liabilities Change 21.29 % -62.17 % -17.36 % 23.99 % -71.16 %
Seq. Cash & cash equivalent Change 18.42 % -1.44 % -38.14 % -38.57 % 61.28 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 106
Healthcare Sector # 574
Overall Market # 1674


Quick Ratio Statistics
High Average Low
51.82 12.59 0.24
(Sep 30 2015)   (Jun 30 2024)




Financial Statements
Atara Biotherapeutics Inc 's Current Liabilities $ 7 Millions Visit ATRA's Balance sheet
Atara Biotherapeutics Inc 's Cash & cash equivalent $ 10 Millions Visit ATRA's Balance sheet
Source of ATRA's Sales Visit ATRA's Sales by Geography


Cumulative Atara Biotherapeutics Inc 's Quick Ratio

ATRA's Quick Ratio for the trailling 12 Months

ATRA Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -87.21 % -89.13 % -84.16 % -65.26 % -35.3 %
Y / Y Cash & cash equivalent TTM Growth -72.26 % -66.71 % -69.48 % -53.92 % -38.11 %
Quick Ratio TTM 0.89 0.99 0.6 0.42 0.41
Total Ranking TTM # 1582 # 2385 # 2242 # 2261 # 2451
Seq. Current Liabilities TTM Growth -14.51 % -45.75 % -54.97 % -38.78 % -27.32 %
Seq. Cash & cash equivalent TTM Growth -23.49 % -9.39 % -36.82 % -36.67 % -8.17 %

Quick ratio ranking by company, industry and sector >> Back to ATRA Financial Strength Comparisons >> Go to Compare ATRA Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in ATRA's Current Liabilities to $6.85 millions, cumulative Quick Ratio to 0.89 below the ATRA average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 142 other companies have achieved higher Quick Ratio than Atara Biotherapeutics Inc . While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending first quarter 2026 at 3863.

Explain Quick Ratio?
How much Cash & cash equivalents ATRA´s has?
What are ATRA´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 143
Healthcare Sector # 900
Within the Market # 1684


trailing twelve months Quick Ratio Statistics
High Average Low
5.61 2.04 0.22
(Dec 31 2015)   (Sep 30 2024)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Biotechnology & Pharmaceuticals Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Adaptive Biotechnologies Corporation  3.92 $ 344.255  Millions$ 87.712  Millions
Immunocore Holdings Plc  3.74 $ 880.211  Millions$ 235.198  Millions
Entera Bio Ltd   3.50 $ 11.309  Millions$ 3.235  Millions
Exozymes Inc   3.49 $ 5.653  Millions$ 1.618  Millions
Acumen Pharmaceuticals Inc   3.44 $ 160.954  Millions$ 46.848  Millions
Century Therapeutics inc   3.29 $ 49.642  Millions$ 15.068  Millions
Adma Biologics Inc   3.26 $ 136.020  Millions$ 41.690  Millions
Tscan Therapeutics Inc   3.23 $ 100.156  Millions$ 30.964  Millions
Sutro Biopharma Inc   3.11 $ 164.346  Millions$ 52.898  Millions
Editas Medicine Inc   3.09 $ 211.645  Millions$ 68.434  Millions
Autolus Therapeutics Plc  2.93 $ 201.630  Millions$ 68.790  Millions
Moderna Inc   2.73 $ 6,910.000  Millions$ 2,534.000  Millions
Sana Biotechnology Inc   2.59 $ 320.990  Millions$ 123.752  Millions
Tarsus Pharmaceuticals Inc   2.56 $ 449.690  Millions$ 175.753  Millions
Meiragtx Holdings Plc  2.46 $ 143.166  Millions$ 58.096  Millions
Kodiak Sciences Inc   2.39 $ 125.903  Millions$ 52.770  Millions
Exelixis Inc   2.32 $ 839.385  Millions$ 361.927  Millions
Precision Biosciences Inc  2.19 $ 87.549  Millions$ 39.886  Millions
Novavax inc   2.18 $ 719.340  Millions$ 330.574  Millions
Regenxbio Inc   2.11 $ 174.530  Millions$ 82.621  Millions
Biocardia Inc   2.00 $ 4.117  Millions$ 2.055  Millions
Kymera Therapeutics Inc   1.75 $ 124.477  Millions$ 71.326  Millions
Biocryst Pharmaceuticals Inc   1.69 $ 353.279  Millions$ 208.846  Millions
Coherus Oncology inc   1.69 $ 127.683  Millions$ 75.510  Millions
Bio techne Corp  1.62 $ 264.712  Millions$ 163.700  Millions
Atara Biotherapeutics Inc   1.45 $ 9.900  Millions$ 6.847  Millions
Twist Bioscience Corporation  1.39 $ 166.839  Millions$ 120.255  Millions
Neumora Therapeutics Inc   1.34 $ 116.834  Millions$ 87.478  Millions
Calidi Biotherapeutics Inc   1.33 $ 4.290  Millions$ 3.237  Millions
Passage Bio Inc   1.17 $ 24.155  Millions$ 20.719  Millions

Date modified: 2026-09-12T06:12:35+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.